• Publications
  • Influence
Bioequivalence and the immunogenicity of biopharmaceuticals
  • H. Schellekens
  • Biology, Medicine
  • Nature Reviews Drug Discovery
  • 1 June 2002
The expiry of the first patents for recombinant-DNA-derived biopharmaceuticals will open the possibility of marketing generics, if they can be shown to be essentially similar to the innovatorExpand
  • 460
  • 22
  • PDF
γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites
This study was designed to test the hypothesis that T-cell effector mechanisms are required for protective immunity to malaria sporozoites. Administration of neutralizing monoclonal antibodiesExpand
  • 654
  • 14
Immunogenicity of therapeutic proteins: clinical implications and future prospects.
BACKGROUND Therapeutic proteins have revolutionized the treatment of many diseases. In the near future, many more therapeutic proteins are likely to become available for an increasingly wide range ofExpand
  • 466
  • 13
Structure-Immunogenicity Relationships of Therapeutic Proteins
As more recombinant human proteins become available on the market, the incidence of immunogenicity problems is rising. The antibodies formed against a therapeutic protein can result in seriousExpand
  • 495
  • 12
Immunogenicity of recombinant human proteins: causes and consequences
Abstract.Antibodies develop to varying degrees during treatment with human proteins, including insulin, growth hormone, granulocyte-macrophage colony-stimulating factor, factor VIII, erythropoietin,Expand
  • 139
  • 7
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.
Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generallyExpand
  • 88
  • 7
The hepatitis delta (δ) virus possesses a circular RNA
Hepatitis delta (δ) virus (HDV), a satellite virus of the hepatitis B virus (HBV), causes a severe form of viral hepatitis in humans1. Here we present evidence based on electron microscopy andExpand
  • 276
  • 6
The safety of switching between therapeutic proteins
Introduction: The approval of several biosimilars in the past years has prompted discussion on potential safety risks associated with switching to and from these products. It has been suggested thatExpand
  • 93
  • 6
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon.
A specific DNA probe was used to study the effect of recombinant rat, mouse, and human gamma-interferon (gamma-IFN) on the course of sporozoite-induced malaria infections. In mice and rats infectedExpand
  • 303
  • 5
Factors influencing the immunogenicity of therapeutic proteins.
  • H. Schellekens
  • Medicine
  • Nephrology, dialysis, transplantation : official…
  • 1 June 2005
Several diseases and disorders are treatable with therapeutic proteins, but some of these products may induce an immune response, especially when administered as multiple doses over prolongedExpand
  • 281
  • 5
...
1
2
3
4
5
...